Letter to the editor referring to the publication entitled “The
role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and
neck cancer treatment” by Pai et al.

J 2016

Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.

SZTURZ, Petr a S. FAIVRE

Základní údaje

Originální název

Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.

Autoři

SZTURZ, Petr (203 Česká republika, garant, domácí) a S. FAIVRE (250 Francie)

Vydání

Oral Oncology, Amsterdam, Elsevier Science BV, 2016, 1368-8375

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.794

Kód RIV

RIV/00216224:14110/16:00092818

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.oraloncology.2016.08.007

UT WoS

000392635300002

Klíčová slova anglicky

squamous-cell carcinoma; recurrent; methotrexate; trial

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 3. 2017 09:23, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator’s choice (single-agent chemotherapy or cetuximab) [1–4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.

Citovat

SZTURZ, Petr a S. FAIVRE. Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al. Oral Oncology. Amsterdam: Elsevier Science BV, 2016, roč. 62, "neuvedeno", s. "e3"-"e4", 2 s. ISSN 1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2016.08.007.

@article{1367429,
   author = {Szturz, Petr and Faivre, S.},
   article_location = {Amsterdam},
   article_number = {"neuvedeno"},
   doi = {http://dx.doi.org/10.1016/j.oraloncology.2016.08.007},
   keywords = {squamous-cell carcinoma; recurrent; methotrexate; trial},
   language = {eng},
   issn = {1368-8375},
   journal = {Oral Oncology},
   title = {Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.},
   volume = {62},
   year = {2016}
}

TY  - JOUR
ID  - 1367429
AU  - Szturz, Petr - Faivre, S.
PY  - 2016
TI  - Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al.
JF  - Oral Oncology
VL  - 62
IS  - "neuvedeno"
SP  - "e3"-"e4"
EP  - "e3"-"e4"
PB  - Elsevier Science BV
SN  - 13688375
KW  - squamous-cell carcinoma
KW  - recurrent
KW  - methotrexate
KW  - trial
N2  - As addressed by Pai with co-workers in their comprehensive review, novel immunotherapeutic strategies using immune checkpoint inhibitors represent a promising area of research in squamous cell carcinoma of the head and neck (SCCHN) [1]. Results from a phase III trial and preliminary data from three early clinical studies demonstrated the efficacy of monoclonal antibodies against programmed death-1 (PD-1) receptor (nivolumab, pembrolizumab) and its ligand PD-L1 (durvalumab) as second-line treatments in the recurrent and/or metastatic (R/M) setting. With relatively low incidence of serious adverse events, these agents elicited durable responses even in patients with refractory disease. Moreover, nivolumab, as the first drug ever, significantly improved overall survival (OS) by 2.4 months compared with investigator’s choice (single-agent chemotherapy or cetuximab) [1–4]. From a broader perspective, these pioneering studies have important implications for future trial design with one of the challenges being the selection of appropriate clinical endpoints associated with benefits of immune checkpoint inhibitors.
ER  -

SZTURZ, Petr a S. FAIVRE. Letter to the editor referring to the publication entitled “The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment” by Pai et al. \textit{Oral Oncology}. Amsterdam: Elsevier Science BV, 2016, roč.~62, ''neuvedeno'', s.~''e3''-''e4'', 2 s. ISSN~1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2016.08.007.

Podrobný výpis o publikaci